IL262565A - Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide - Google Patents

Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Info

Publication number
IL262565A
IL262565A IL262565A IL26256518A IL262565A IL 262565 A IL262565 A IL 262565A IL 262565 A IL262565 A IL 262565A IL 26256518 A IL26256518 A IL 26256518A IL 262565 A IL262565 A IL 262565A
Authority
IL
Israel
Prior art keywords
difluoroacetamide
dioxopiperidin
oxoisoindolin
chlorophenyl
methyl
Prior art date
Application number
IL262565A
Other languages
Hebrew (he)
Other versions
IL262565B (en
Inventor
Michael Pourdehnad
Kyle Macbeth
Antonia Lopez-Girona
Gang Lu
Soraya Carrancio
Paul Hollenbach
Irit Rappley
Original Assignee
Celgene Corp
Michael Pourdehnad
Kyle Macbeth
Lopez Girona Antonia
Gang Lu
Soraya Carrancio
Paul Hollenbach
Irit Rappley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Michael Pourdehnad, Kyle Macbeth, Lopez Girona Antonia, Gang Lu, Soraya Carrancio, Paul Hollenbach, Irit Rappley filed Critical Celgene Corp
Publication of IL262565A publication Critical patent/IL262565A/en
Publication of IL262565B publication Critical patent/IL262565B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL262565A 2016-06-06 2017-06-05 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide IL262565B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662346344P 2016-06-06 2016-06-06
PCT/US2017/035892 WO2017214014A1 (en) 2016-06-06 2017-06-05 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Publications (2)

Publication Number Publication Date
IL262565A true IL262565A (en) 2018-12-31
IL262565B IL262565B (en) 2022-08-01

Family

ID=60482040

Family Applications (1)

Application Number Title Priority Date Filing Date
IL262565A IL262565B (en) 2016-06-06 2017-06-05 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Country Status (15)

Country Link
US (4) US10245258B2 (en)
EP (1) EP3463358A4 (en)
JP (1) JP7163281B2 (en)
KR (1) KR20190015300A (en)
CN (2) CN115282149A (en)
AU (2) AU2017278114B2 (en)
BR (1) BR112018075206A2 (en)
CA (1) CA3026396A1 (en)
CL (1) CL2018003499A1 (en)
EA (1) EA201892746A1 (en)
IL (1) IL262565B (en)
MX (1) MX2018015120A (en)
SG (1) SG11201809501PA (en)
WO (1) WO2017214014A1 (en)
ZA (1) ZA201807105B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2017120446A1 (en) * 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
US11535603B1 (en) 2016-09-30 2022-12-27 Deuterx, Llc Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same
MX2021007800A (en) * 2018-12-31 2021-10-26 Celgene Corp Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-5yl) methyl)-2,2-difluoroace tamide.
IL292765A (en) * 2019-11-05 2022-07-01 Celgene Corp Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
BR112022010019A2 (en) 2019-12-06 2022-08-16 Celgene Corp PROCESSES FOR PREPARING 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE
CN115515582A (en) * 2020-03-16 2022-12-23 细胞基因公司 Combination therapy for acute myeloid leukemia
JP2023542930A (en) * 2020-09-23 2023-10-12 セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド Substituted N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
KR20240066906A (en) * 2022-11-08 2024-05-16 주식회사 온코드바이오 Isoindolinone compounds with substituted quinoline amide and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002363959B2 (en) * 2001-12-03 2007-12-13 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20090175869A1 (en) * 2007-05-31 2009-07-09 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
CA2762458C (en) 2009-05-20 2018-08-28 Hybrigenics Sa New therapeutical uses of inecalcitol
SG11201401946QA (en) * 2011-11-01 2014-05-29 Celgene Corp Methods for treating cancers using oral formulations of cytidine analogs
LT3077004T (en) * 2013-12-05 2020-05-11 F. Hoffmann-La Roche Ag Novel combination treatment for acute myeloid leukemia (aml)
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
ES2832475T3 (en) 2016-01-08 2021-06-10 Celgene Corp Antiproliferative Compounds and Their Pharmaceutical Compositions and Uses
CA3010794A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
EA037508B1 (en) * 2016-01-08 2021-04-06 Селджин Корпорейшн Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Also Published As

Publication number Publication date
US11590117B2 (en) 2023-02-28
JP2019517587A (en) 2019-06-24
US20170348298A1 (en) 2017-12-07
CN115282149A (en) 2022-11-04
WO2017214014A1 (en) 2017-12-14
EA201892746A1 (en) 2019-06-28
US10245258B2 (en) 2019-04-02
KR20190015300A (en) 2019-02-13
IL262565B (en) 2022-08-01
CN109414436A (en) 2019-03-01
MX2018015120A (en) 2019-04-15
SG11201809501PA (en) 2018-12-28
AU2023202159A1 (en) 2023-05-04
CA3026396A1 (en) 2017-12-14
ZA201807105B (en) 2020-01-29
CL2018003499A1 (en) 2019-03-15
AU2017278114A1 (en) 2018-11-29
AU2017278114B2 (en) 2023-01-12
US20190175573A1 (en) 2019-06-13
US20210154182A1 (en) 2021-05-27
BR112018075206A2 (en) 2019-03-19
US20230158009A1 (en) 2023-05-25
EP3463358A4 (en) 2020-07-22
JP7163281B2 (en) 2022-10-31
EP3463358A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
ZA201807105B (en) Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
HRP20181143T1 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
ZA201804482B (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
MA47575A (en) MONOCYCLIC OGA INHIBITOR COMPOUNDS
KR102060995B9 (en) User interface for managing controllable external devices
IL257282B (en) 2-(4-aminocyclohexylamino)-4-(pyrazol-4-yl)pyrimidine compounds
SI3644999T1 (en) Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
EP3735243A4 (en) Isotopologues of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
IL284509A (en) Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5yl) methyl)-2,2-difluoroacetamide
EP4054578A4 (en) Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
GB2550399B (en) A novel form of sulfentrazone, a process for its preparation and use the same
HK1246290A1 (en) Process for the preparation of 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-l-alanyl-l-alaninate monohydrochloride
IL265893A (en) Crystalline forms of 4-(2-((1r,2r)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-n-methylpicolinamide
PL3105243T3 (en) 2',3'-dideoxy-5-fluorouridine derivatives, a process for the manufacture thereof and application thereof
PT3395818T (en) 2-(morpholin-4-yl)-1,7-naphthyridines
UA34481S (en) EARRINGS "MEET ELEGANCE"
UA34149S (en) PACKAGING FOR COFFEE "VOMVENE AFRICA"
UA32691S (en) BROOCH "O.W. GRANT"
ITUA20162299A1 (en) MANUFACTURE FOR THE CONTAINMENT OF A SALMA.
UA32441S (en) LOGO "PARAMEDIC"
MA43553A (en) 2- (MORPHOLIN-4-YL) -1,7-NAPHTHYRIDINES